Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study

BACKGROUND: NVX-CoV2373, a Covid-19 vaccine was developed in the USA with ∼90% efficacy. The same vaccine is manufactured in India after technology transfer (called as SII-NVX-CoV2373), was evaluated in this phase 2/3 immuno-bridging study. METHODS: This was an observer-blind, randomised, phase 2/3...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Prasad S., Kadam, Abhijit, Godbole, Sheela, Bhatt, Varsha, Raut, Abhishek, Kohli, Sunil, Tripathi, Santanu, Kulkarni, Praveen, Ludam, Rakhi, Prabhu, Madhav, Bavdekar, Ashish, Gogtay, Nithya J., Meshram, Sushant, Kadhiravan, Tamilarasu, Kar, Sonali, Narayana, D.H. Ashwath, Samuel, Clarence, Kulkarni, Govind, Gaidhane, Abhay, Sathyapalan, Dipu, Raut, Sidram, Hadda, Vijay, Bhalla, Hira Lal, Bhamare, Chetanraj, Dharmadhikari, Abhijeet, Plested, Joyce S., Cloney-Clarke, Shane, Zhu, Mingzhu, Pryor, Melinda, Hamilton, Stephanie, Thakar, Madhuri, Shete, Ashwini, Gautam, Manish, Gupta, Nivedita, Panda, Samiran, Shaligram, Umesh, Poonawalla, Cyrus S., Bhargava, Balram, Gunale, Bhagwat, Kapse, Dhananjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833646/
https://www.ncbi.nlm.nih.gov/pubmed/36647543
http://dx.doi.org/10.1016/j.lansea.2022.100139

Ejemplares similares

Ejemplares similares